Evidence map›Paper›PMID 27708377›Full record

Trial reportScientific reports2016

Postoperative hormonal therapy prevents recovery of neurological damage after surgery in patients with breast cancer.

Atsushi Sekiguchi, Chiho Sato, Izumi Matsudaira, Yuka Kotozaki, Rui Nouchi, Hikaru Takeuchi, Masaaki Kawai, Hiroshi Tada, Takanori Ishida, Yasuyuki Taki and 2 more

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Age as a moderator of neurocognitive performance in patients with large B-cell lymphoma treated with axicabtagene ciloleucel.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Atsushi SekiguchiDepartment of Adult Mental Health, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.
Chiho SatoDepartment of Functional Brain Imaging, Institute of Development, Aging and Cancer (IDAC), Tohoku University, Sendai, Japan.
Izumi MatsudairaDepartment of Nuclear Medicine and Radiology, IDAC, Tohoku University, Sendai, Japan.
Yuka KotozakiDivision of Clinical Research, Medical-Industry Translational Research Center, Fukushima Medical University School of Medicine, Fukushima, Japan.
Rui NouchiCreative Interdisciplinary Research Division, Frontier Research Institute for Interdisciplinary Science, Tohoku University, Sendai, Japan.
Hikaru TakeuchiDivision of Developmental Cognitive Neuroscience, IDAC, Tohoku University, Sendai, Japan.
Masaaki KawaiDepartment of Breast Oncology, Miyagi Cancer Center Hospital, Miyagi, Japan.
Hiroshi TadaDivision of Surgical Oncology, Graduate School of Medicine, Tohoku University, Sendai, Japan.
Takanori IshidaDivision of Surgical Oncology, Graduate School of Medicine, Tohoku University, Sendai, Japan.
Yasuyuki TakiDivision of Medical Neuroimage Analysis, Department of Community Medical Supports, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Noriaki OhuchiDivision of Surgical Oncology, Graduate School of Medicine, Tohoku University, Sendai, Japan.
Ryuta KawashimaDepartment of Functional Brain Imaging, Institute of Development, Aging and Cancer (IDAC), Tohoku University, Sendai, Japan.
Tohoku University · JPFukushima Medical University · JPMiyagi Prefectural Hospital Organization · JPNational Institute of Mental Health · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer survivors are exposed to several risk factors for cognitive dysfunction, such as general anesthesia, surgical trauma, and adjuvant therapies. In our recent study we showed that thalamic volume reduction and attentional dysfunction occurred shortly after surgery. Here, we examined the 6-month prognosis of the 20 patients with breast cancer who underwent surgery. Seven patients did not receive any adjuvant therapy after the surgery and 13 patients received a hormonal therapy after the surgery. We assessed their attentional functions, and thalamic volumes shortly after and 6 months after surgery. We found a significant group x time interaction in the attentional functions (p = 0.033) and the right thalamus (p <  0.05, small volume correction), suggesting the thalamic volume reduction and attentional dysfunction recovered in patients without adjuvant therapy. Our findings provide a better understanding of the potential role of hormonal therapy in relation to the cognitive dysfunction of cancer survivors.

Indexed as

AgedBreast NeoplasmsChemotherapy, AdjuvantCognitive DysfunctionCombined Modality TherapyFemaleHormone AntagonistsHumansMiddle AgedPostoperative PeriodPrognosisQuality of LifeRecovery of FunctionThalamusHormone Antagonists

Identifiers

PMID27708377
PMCPMC5052558
OpenAlexW2528552868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.